Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice.

Regina A, Demeule M, Tripathy S, Lord-Dufour S, Currie JC, Iddir M, Annabi B, Castaigne JP, Lachowicz JE.

Mol Cancer Ther. 2015 Jan;14(1):129-40. doi: 10.1158/1535-7163.MCT-14-0399. Epub 2014 Dec 9.

PMID:
25492620
2.

New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.

Ché C, Yang G, Thiot C, Lacoste MC, Currie JC, Demeule M, Régina A, Béliveau R, Castaigne JP.

J Med Chem. 2010 Apr 8;53(7):2814-24. doi: 10.1021/jm9016637.

PMID:
20210346
3.

Transport characteristics of a novel peptide platform for CNS therapeutics.

Bertrand Y, Currie JC, Demeule M, Régina A, Ché C, Abulrob A, Fatehi D, Sartelet H, Gabathuler R, Castaigne JP, Stanimirovic D, Béliveau R.

J Cell Mol Med. 2010 Dec;14(12):2827-39. doi: 10.1111/j.1582-4934.2009.00930.x.

4.

Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.

Gabathuler R.

Neurobiol Dis. 2010 Jan;37(1):48-57. doi: 10.1016/j.nbd.2009.07.028. Epub 2009 Aug 5. Review.

PMID:
19664710
5.

Blood-brain barrier transport of drugs for the treatment of brain diseases.

Gabathuler R.

CNS Neurol Disord Drug Targets. 2009 Jun;8(3):195-204. Review.

PMID:
19601817
6.

Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2.

Demeule M, Currie JC, Bertrand Y, Ché C, Nguyen T, Régina A, Gabathuler R, Castaigne JP, Béliveau R.

J Neurochem. 2008 Aug;106(4):1534-44. doi: 10.1111/j.1471-4159.2008.05492.x. Epub 2008 May 19.

PMID:
18489712
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk